Real-world evidence of nivolumab monotherapy in advanced renal cell carcinoma from a multicenter retrospective cohort study by the Spanish Genitourinary Oncology Group.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fernández-Díaz Natalia, Mateos-González María, Pertejo-Fernández Ana, Cacho-Lavín Juan Diego, Juan-Fita María José, Chirivella-González Isabel, Arruti-Ibarbia Mikel, Fernández-Calvo Ovidio, Fernández-Núñez Natalia, Méndez-Vidal María José, Lázaro-Quintela Martín, Molina-Díaz Aurea, Del Pozo-Alonso Nieves, Etxaniz-Ulazia Olatz, García-Acuña Silvia Margarita, Betancor Yoel Z, Azueta-Etxebarria Ainara, Calatrava-Fons Ana, Lombardía-Rodríguez Helena, Alarcón-Molero Lorena, Etxegarai-Ganboa Leire, Antón-Cameselle Abraham, Bello-Giz José Antonio, Neira-De Paz Carlos Manuel, Cabaleiro Teresa, González-Serrano Teresa, Ortiz-Rey José Antonio, Sacristán-Lista Felipe, García-Rubín Silvia, Ortega Elisa, Carrato-Moñino Cristina, Aguín-Losada Santiago, León-Mateos Luis, García-González Jorge, Pinto-Marín Álvaro, Duran Ignacio, López-López Rafael, Anido-Herranz Urbano, Ruiz-Bañobre Juan
Аннотация
PATIENTS AND METHODS: We conducted a multicenter, retrospective study of 222 previously treated aRCC patients to assess the efficacy of nivolumab and the influence of pre-treatment factors on clinical outcomes across 13 Spanish centers. Eligible patients had received at least one dose of nivolumab in routine clinical practice. Demographic, clinical, and laboratory data were extracted from electronic records. Efficacy endpoints were overall survival (OS), progression-free survival (PFS), disease control rate (DCR), and overall response rate (ORR). Survival estimates were calculated by the Kaplan-Meier method, and groups were compared with the log-rank test. The Cox proportional hazards regression model was used to evaluate factors independently associated with OS. Factors associated with disease control (DC) and response were tested with logistic regression in univariable and multivariable analyses. Comparisons between patient and disease characteristics were carried out using Fisher's exact test. All P values were two-sided, and those < 0.05 were considered statistically significant. Results were contextualized with key clinical experiences involving nivolumab monotherapy in aRCC.
RESULTS: With a median follow-up of 14.6 months, median overall survival (OS) was 18.1 months (95% confidence interval [CI], 14.2-23.7 months), and median progression-free survival (PFS) was 4.96 months (95% CI, 3.98-7.13). The disease control rate was 51% (95% CI, 45-58%), and the objective response rate was 23% (95% CI, 18-30%). Poor International Metastatic RCC Database Consortium (IMDC) risk score was independently associated with shorter OS, while prior nephrectomy predicted improved OS. Poor IMDC risk and ≥ 3 metastatic sites were independently associated with shorter PFS; ≥ 3 metastatic sites also correlated with reduced disease control.
CONCLUSION: Consistent with previous clinical trials and RWE studies, our findings reinforce the efficacy of nivolumab in routine clinical practice for an unselected cohort of previously treated aRCC patients in Spain.